胃肠道恶性肿瘤患者当日使用peg非格昔汀与同时使用卡培他滨的首次分析。

Cancer medicine journal Pub Date : 2021-03-01 Epub Date: 2020-12-30
Muhammad Wasif Saif, Nausheen Hakim, Jeffrey Chi, Hasan Rehman, Shreya Prasad Goyal, Coral Olazagasti, Patnita Forde Sheperd, Jyothi Jose
{"title":"胃肠道恶性肿瘤患者当日使用peg非格昔汀与同时使用卡培他滨的首次分析。","authors":"Muhammad Wasif Saif,&nbsp;Nausheen Hakim,&nbsp;Jeffrey Chi,&nbsp;Hasan Rehman,&nbsp;Shreya Prasad Goyal,&nbsp;Coral Olazagasti,&nbsp;Patnita Forde Sheperd,&nbsp;Jyothi Jose","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pegfilgrastim is administered 24 hours. after chemotherapy to reduce risks of myelosuppression. This requires an additional clinic visit, which can be difficult for some patients (pts) due to work and transportation issues. In GI malignancies, patients receiving capecitabine-based regimens also require pegfilgrastim to reduce myelotoxicity. We present here the first study to analyze safety and efficacy of administering pegfilgrastim on the same day as capecitabine-based regimens in patients with GI malignancies.</p><p><strong>Methods: </strong>We evaluated 157 patients with GI malignancies who received a capecitabine-based chemotherapy regimen, including XELOX, EOX, ECX, XELIRI, MIXE, gemcitabine-capecitabine and same-day pegfilgrastim (6 mg) within 1 hr of completion of systemic agents. As per institutional guidelines, patients were counseled on risks of same-day pegfilgrastim prior to its administration. Patients were followed to determine the degree of neutropenia and toxicity.</p><p><strong>Results: </strong>A total of 914 chemotherapy cycles in 157 patients were analyzed. Median ANC nadir for all cycles was 5634/uL (range: 450 - 23800). Grade 1 and 2 neutropenia developed in 11 of 914 cycles. Bone pain reported in 9 pts. There was 1 episode of grade >3 neutropenia resulting in infection and antibiotic use. No other patient required dose reductions, chemotherapy delays, or hospitalizations. No increased toxicity of capecitabine was noticed.</p><p><strong>Conclusions: </strong>We believe our study is the first in GI malignancies to report that same-day pegfilgrastim administration with capecitabine-based regimens may be as effective and safe as next-day administration. Additionally, given the absence of CD in human bone marrow, it appears capecitabine can be used concurrently with pegfilgrastim. Prospective studies should be done to further investigate, as this practice can benefit patients clinically, decrease office visits, increase patient's satisfaction and reduce healthcare costs.</p>","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903891/pdf/nihms-1662938.pdf","citationCount":"0","resultStr":"{\"title\":\"First Analysis of Same-day Pegfilgrastim Use with Concurrent Capecitabine-based Regimens in Patients with Gastrointestinal Malignancies.\",\"authors\":\"Muhammad Wasif Saif,&nbsp;Nausheen Hakim,&nbsp;Jeffrey Chi,&nbsp;Hasan Rehman,&nbsp;Shreya Prasad Goyal,&nbsp;Coral Olazagasti,&nbsp;Patnita Forde Sheperd,&nbsp;Jyothi Jose\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Pegfilgrastim is administered 24 hours. after chemotherapy to reduce risks of myelosuppression. This requires an additional clinic visit, which can be difficult for some patients (pts) due to work and transportation issues. In GI malignancies, patients receiving capecitabine-based regimens also require pegfilgrastim to reduce myelotoxicity. We present here the first study to analyze safety and efficacy of administering pegfilgrastim on the same day as capecitabine-based regimens in patients with GI malignancies.</p><p><strong>Methods: </strong>We evaluated 157 patients with GI malignancies who received a capecitabine-based chemotherapy regimen, including XELOX, EOX, ECX, XELIRI, MIXE, gemcitabine-capecitabine and same-day pegfilgrastim (6 mg) within 1 hr of completion of systemic agents. As per institutional guidelines, patients were counseled on risks of same-day pegfilgrastim prior to its administration. Patients were followed to determine the degree of neutropenia and toxicity.</p><p><strong>Results: </strong>A total of 914 chemotherapy cycles in 157 patients were analyzed. Median ANC nadir for all cycles was 5634/uL (range: 450 - 23800). Grade 1 and 2 neutropenia developed in 11 of 914 cycles. Bone pain reported in 9 pts. There was 1 episode of grade >3 neutropenia resulting in infection and antibiotic use. No other patient required dose reductions, chemotherapy delays, or hospitalizations. No increased toxicity of capecitabine was noticed.</p><p><strong>Conclusions: </strong>We believe our study is the first in GI malignancies to report that same-day pegfilgrastim administration with capecitabine-based regimens may be as effective and safe as next-day administration. Additionally, given the absence of CD in human bone marrow, it appears capecitabine can be used concurrently with pegfilgrastim. Prospective studies should be done to further investigate, as this practice can benefit patients clinically, decrease office visits, increase patient's satisfaction and reduce healthcare costs.</p>\",\"PeriodicalId\":72513,\"journal\":{\"name\":\"Cancer medicine journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903891/pdf/nihms-1662938.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer medicine journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/12/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer medicine journal","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/12/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:Pegfilgrastim给药24小时。化疗后降低骨髓抑制风险。这需要额外的诊所访问,由于工作和交通问题,这对一些患者(患者)来说可能很困难。在胃肠道恶性肿瘤中,接受卡培他滨为基础的方案的患者也需要pegfilgrastim来降低骨髓毒性。我们在这里提出了第一项研究,分析了胃肠道恶性肿瘤患者在同一天给予pegfilgrastim与卡培他滨为基础的方案的安全性和有效性。方法:我们评估了157例胃肠道恶性肿瘤患者,他们接受了以卡培他滨为基础的化疗方案,包括XELOX、EOX、ECX、XELIRI、MIXE、吉西他滨-卡培他滨和当日pegfilgrastim (6 mg),完成全身药物治疗后1小时内。根据机构指南,患者在给药前被告知当日服用pegfilgrastim的风险。随访患者以确定中性粒细胞减少程度和毒性。结果:157例患者共914个化疗周期。所有周期的中位数ANC最低点为5634/uL(范围:450 - 23800)。914个周期中有11个出现1级和2级中性粒细胞减少症。9例患者报告骨痛。有1例>3级中性粒细胞减少导致感染和使用抗生素。没有其他患者需要减少剂量、化疗延迟或住院治疗。未发现卡培他滨毒性增加。结论:我们相信我们的研究是第一个在胃肠道恶性肿瘤中报告当天给药pegfilgrastim与卡培他滨为基础的方案可能与第二天给药一样有效和安全的研究。此外,鉴于人骨髓中不存在CD,卡培他滨似乎可以与聚非格拉西汀同时使用。应该进行前瞻性研究以进一步调查,因为这种做法可以使患者在临床上受益,减少办公室就诊,提高患者满意度并降低医疗保健成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
First Analysis of Same-day Pegfilgrastim Use with Concurrent Capecitabine-based Regimens in Patients with Gastrointestinal Malignancies.

Background: Pegfilgrastim is administered 24 hours. after chemotherapy to reduce risks of myelosuppression. This requires an additional clinic visit, which can be difficult for some patients (pts) due to work and transportation issues. In GI malignancies, patients receiving capecitabine-based regimens also require pegfilgrastim to reduce myelotoxicity. We present here the first study to analyze safety and efficacy of administering pegfilgrastim on the same day as capecitabine-based regimens in patients with GI malignancies.

Methods: We evaluated 157 patients with GI malignancies who received a capecitabine-based chemotherapy regimen, including XELOX, EOX, ECX, XELIRI, MIXE, gemcitabine-capecitabine and same-day pegfilgrastim (6 mg) within 1 hr of completion of systemic agents. As per institutional guidelines, patients were counseled on risks of same-day pegfilgrastim prior to its administration. Patients were followed to determine the degree of neutropenia and toxicity.

Results: A total of 914 chemotherapy cycles in 157 patients were analyzed. Median ANC nadir for all cycles was 5634/uL (range: 450 - 23800). Grade 1 and 2 neutropenia developed in 11 of 914 cycles. Bone pain reported in 9 pts. There was 1 episode of grade >3 neutropenia resulting in infection and antibiotic use. No other patient required dose reductions, chemotherapy delays, or hospitalizations. No increased toxicity of capecitabine was noticed.

Conclusions: We believe our study is the first in GI malignancies to report that same-day pegfilgrastim administration with capecitabine-based regimens may be as effective and safe as next-day administration. Additionally, given the absence of CD in human bone marrow, it appears capecitabine can be used concurrently with pegfilgrastim. Prospective studies should be done to further investigate, as this practice can benefit patients clinically, decrease office visits, increase patient's satisfaction and reduce healthcare costs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
ANK Therapeutic Prospects and Usefulness of PD-L1 and NK Activity as Biomarkers for Predicting Treatment Efficacy Revealed from the Treatment Course of Patients with HTLV-1-Associated Bronchioloalveolar Disease. Psychological Distress and Suicide Correlated with Long-Life Expectancy in Advanced Cancer Patients A Comprehensive Review of Management of Colorectal Liver Mets in the Current Era. Synchronous Duodenal and Jejunal Gastrointestinal Stromal Tumors Impact of Using Median vs. Mean in Calculating ERBB2 FISH Results in Breast Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1